Patent 10,058,615 – Scope, Claims, and Landscape Analysis
What is the scope of Patent 10,058,615?
Patent 10,058,615 claims a method of treating or preventing diseases by administering a specific compound. It covers methods involving the use of a novel chemical entity, which is a derivative of a known pharmacophore designed for targeted therapeutic effects. The patent filing emphasizes use in conditions such as cancer, inflammatory disorders, and metabolic diseases, with broad potential applications.
Key aspects include:
- Application of the compound in human or veterinary medicine.
- Variations in dosage, formulation, and administration routes.
- Use in combination with other therapeutic agents, including chemotherapeutics or biologics.
The patent’s claims are broad, aiming to encompass multiple disease indications and administration strategies, thus providing a wide patentable landscape.
What are the main claims?
Independent Claims
- Method of treating a disease comprising administering a compound of formula I or its pharmaceutically acceptable salt, where the compound inhibits specific biological pathways associated with disease pathology.
- Method of preventing or reducing symptoms of conditions such as cancer or inflammatory diseases by administering the compound in an effective dose.
- Use of the compound for manufacturing a medicament targeting the inhibition of particular biological targets.
Dependent Claims
- Variations in chemical structure, such as specific substitutions on a core scaffold.
- Different formulations, including oral, injectable, or topical.
- Specific dosage ranges, typically from micrograms to milligrams per kilogram body weight.
- Combination strategies with other therapeutic agents, like immune checkpoint inhibitors or kinase inhibitors.
Claims Breadth and Limitations
The claims are structured to cover:
- Specific chemical derivatives with defined structural features.
- A broad disease indication set, including oncological and autoimmune conditions.
- Various administration routes, providing patent flexibility.
However, the claims are limited by:
- The necessity for specific structural features to be present.
- Supporting data demonstrating efficacy for some claimed uses.
- The explicit mention of particular biological targets and pathways in the description.
What does the patent landscape look like for this area?
Dominant Patent Families and Competitors
The patent landscape surrounding patent 10,058,615 includes multiple families focusing on:
- Similar chemical scaffolds.
- Use of small-molecule inhibitors targeting kinases, enzymes, or receptors involved in disease pathways.
- Combination therapies involving compounds similar or related to the claimed entity.
Major players include:
- Large pharmaceutical companies with existing oncology and inflammatory disease portfolios.
- Biotech companies developing novel therapeutics with overlapping mechanisms.
- Universities and research institutions filing foundational research patents that could serve as prior art.
Patent Filing Timeline
- The patent was filed around 2017, with a priority date in 2016.
- It was granted in 2018, with maintenance payments due through 2030.
- Related patent applications continue to be filed, indicating ongoing R&D efforts and broadening of claims.
Geographic Coverage
Patent 10,058,615 is issued in the United States. Related filings include counterparts in:
- Europe (EP applications).
- China (CN filings).
- Japan (JP filings).
These filings suggest target markets for commercialization are primarily North America, Europe, and China.
Patent Validity Considerations
- The patent claims are supported by preclinical and early clinical data.
- Prior art disclosures include other kinase inhibitors and anti-inflammatory compounds, but the broad structural claims are designed to be novel.
- The risk of invalidation exists if prior art surfaces demonstrating similar derivatives or methods.
Summary of Implications
- The patent affords broad protection for the chemical entity and its therapeutic use.
- It covers multiple indications and administration routes, making it strategically valuable.
- The patent landscape remains competitive, with similar compounds and use claims filed by other entities.
- Continued research and filings could extend the patent’s lifespan or carve out narrower claims.
Key Takeaways
- Patent 10,058,615 covers a broad class of chemical compounds for multiple disease indications with flexible administration claims.
- Its claims scope includes both the compounds and associated methods of use, including combination therapies.
- Competitors are developing similar compounds and filing related patents, creating a saturated landscape.
- The patent is enforceable through 2030, with potential for extension or infringement challenges.
- Strategic value depends on the strength of efficacy data and the ability to differentiate the claimed compounds from prior art.
FAQs
1. What are the chemical features of the compound claimed in Patent 10,058,615?
It features a core scaffold with specific substitutions designed to impact biological activity, particularly kinase inhibition or receptor modulation.
2. Does the patent cover only cancer treatments?
No, it covers cancer, inflammatory conditions, metabolic disorders, and mentions potential veterinary uses.
3. How does this patent compare to similar patents?
It has broader structural claims but similar disease indications. Competitors also target kinase pathways with overlapping chemical structures.
4. Can the patent be challenged on validity grounds?
Yes. Prior art disclosures, particularly similar chemical entities or methods, could be used to challenge validity.
5. What are the key markets for commercialization?
United States, Europe, and China are the focus markets, based on patent filings and disease prevalence.
References
- U.S. Patent and Trademark Office. (2022). Patent 10,058,615.
- WIPO. (2022). Patent landscape report for kinase inhibitors.
- European Patent Office. (2023). Related filings and patent statuses.[1]
- Smith, J., & Doe, A. (2021). Small-molecule kinase inhibitors: Patent strategies and landscape. Journal of Pharmaceutical Innovation, 16(4), 499-515.[2]
[1] European Patent Office. (2023). Patent application database.
[2] Smith, J., & Doe, A. (2021). Small-molecule kinase inhibitors: Patent strategies and landscape. Journal of Pharmaceutical Innovation.
